Internationale Publikationen
Hier stellen wir eine Auswahl wissenschaftlicher Veröffentlichungen zur Verfügung, die im Zusammenhang mit der IOZK-Immuntherapie stehen.
Sie können mit Hilfe der Filter eine Auswahl nach Tumorarten und Methoden treffen, oder Suchbegriffe eingeben.
Immunotherapy in lung cancer
Fighting fire with fire: the revival of thermotherapy for gliomas
Immunotherapy prospects in the treatment of lung cancer and mesothelioma
Postoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma
Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses
Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8(+) T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model
Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection
Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies
Diffuse intrinsic pontine glioma: time for therapeutic optimism
Tumor cell lysates as immunogenic sources for cancer vaccine design
Antigen trapping by dendritic cells for antitumor therapy
Generation of multiple peptide cocktail-pulsed dendritic cells as a cancer vaccine
Immunotherapy and lung cancer: current developments and novel targeted therapies
Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function
Dendritic cell-based vaccines: clinical applications in breast cancer
Novel dendritic cell-based vaccination in late stage melanoma
Dendritic cell immunotherapy in uterine cancer
Dendritic cells in cancer immunotherapy clinical trials: are we making progress?
Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go
Wilms‘ Tumor Gene 1 (WT1)–loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial